A multi-center, open-label Phase I/II clinical study to determine clinical outcomes of CM380 in patients with relapsed or refractory multiple myeloma
Latest Information Update: 06 Apr 2025
At a glance
- Drugs CM 380 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2025 New trial record
- 26 Mar 2025 According to a Keymed Biosciences media release, as of the date, company is planning to conduct an open-label Phase I/II clinical study for evaluation of CM380 in treatment of patients with relapsed or refractory multiple myeloma.